166 related articles for article (PubMed ID: 18188711)
1. Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care.
Lönnroth C; Svensson M; Wang W; Körner U; Daneryd P; Nilsson O; Lundholm K
Med Oncol; 2008; 25(1):22-9. PubMed ID: 18188711
[TBL] [Abstract][Full Text] [Related]
2. [Research advances in expression and functions of erythropoietin and erythropoietin receptor in cancers].
Li M; Lu Y; Chen XQ
Ai Zheng; 2008 Jun; 27(6):667-72. PubMed ID: 18570746
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia.
Osterborg A; Aapro M; Cornes P; Haselbeck A; Hayward CR; Jelkmann W
Eur J Cancer; 2007 Feb; 43(3):510-9. PubMed ID: 17150352
[TBL] [Abstract][Full Text] [Related]
4. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function.
Lundholm K; Daneryd P; Bosaeus I; Körner U; Lindholm E
Cancer; 2004 May; 100(9):1967-77. PubMed ID: 15112279
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations.
Ahlqvist-Rastad J; Albertsson M; Bergh J; Birgegård G; Johansson P; Jonsson B; Kjellen E; Påhlman S; Zackrisson B; Osterborg A
Med Oncol; 2007; 24(3):267-72. PubMed ID: 17873301
[TBL] [Abstract][Full Text] [Related]
6. [Anaemia and radiation therapy].
Denis F; Lartigau E
Cancer Radiother; 2004 Nov; 8 Suppl 1():S14-23. PubMed ID: 15679242
[TBL] [Abstract][Full Text] [Related]
7. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
Rainville N; Jachimowicz E; Wojchowski DM
Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin use in CKD patients with cancer: to tread with caution?
Nayak-Rao S; McCormick B
J Nephrol; 2013; 26(5):829-35. PubMed ID: 24052463
[TBL] [Abstract][Full Text] [Related]
9. Is recombinant human erythropoietin (rh-epo) more than just a treatment of anemia in cancer and chemotherapy?
Taylor SK
Med Hypotheses; 2003 Jan; 60(1):89-93. PubMed ID: 12450771
[TBL] [Abstract][Full Text] [Related]
10. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Biochim Biophys Acta; 2007 Sep; 1776(1):1-9. PubMed ID: 17683868
[TBL] [Abstract][Full Text] [Related]
11. High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study.
Vannucchi AM; Bosi A; Linari S; Guidi S; Longo G; Lombardini L; Mariani MP; Saccardi R; Laszlo D; Rossi Ferrini P
Haematologica; 1997; 82(1):53-6. PubMed ID: 9107083
[TBL] [Abstract][Full Text] [Related]
12. [Does long-term erythropoietin therapy influence the prevalence of serum markers of hepatitis B and C in haemodialysed uraemic patients?].
Mesjasz J; Wiecek A; Gonciarz Z; Mazur W; Kokot F
Pol Merkur Lekarski; 2004 Apr; 16(94):362-7. PubMed ID: 15517934
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment.
Lisowska KA; Debska-Slizień A; Bryl E; Rutkowski B; Witkowski JM
Artif Organs; 2010 Aug; 34(8):654-62. PubMed ID: 20528849
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction.
Okonko DO; Marley SB; Anker SD; Poole-Wilson PA; Gordon MY
Int J Cardiol; 2013 Apr; 164(3):359-64. PubMed ID: 21821297
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin regulates tumour growth of human malignancies.
Yasuda Y; Fujita Y; Matsuo T; Koinuma S; Hara S; Tazaki A; Onozaki M; Hashimoto M; Musha T; Ogawa K; Fujita H; Nakamura Y; Shiozaki H; Utsumi H
Carcinogenesis; 2003 Jun; 24(6):1021-9. PubMed ID: 12807756
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer.
Saintigny P; Besse B; Callard P; Vergnaud AC; Czernichow S; Colombat M; Girard P; Validire P; Breau JL; Bernaudin JF; Soria JC
Clin Cancer Res; 2007 Aug; 13(16):4825-31. PubMed ID: 17699861
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin receptor and tissue factor are coexpressed in human breast cancer cells.
Wojtukiewicz MZ; Hempel D; Kruszewska J; Zimnoch L; Kisiel W; Sierko E
J BUON; 2015; 20(6):1426-31. PubMed ID: 26854437
[TBL] [Abstract][Full Text] [Related]
19. Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives.
Merchionne F; Dammacco F
Br J Haematol; 2009 Jul; 146(2):127-41. PubMed ID: 19388936
[TBL] [Abstract][Full Text] [Related]
20. The role of erythropoietin and erythropoietin receptor in malignant laryngeal tumors.
Vukelic J; Dobrila-Dintinjana R; Jonjic N; Dekanic A; Ilijic V
Med Hypotheses; 2013 Dec; 81(6):1155-8. PubMed ID: 24134826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
